Overview
Compass Pathways raised approximately $350 million in Q1 2026 through a combination of public stock offerings and warrant exercises, capitalizing on positive Phase 3 trial data for its COMP360 psilocybin therapy targeting treatment-resistant depression (TRD).
The Data
COMP360 is a proprietary synthetic psilocybin formulation administered in a single session with psychological support. The Phase 3 results showed statistically significant and clinically meaningful improvements in depression scores compared to placebo, with effects lasting at least 12 weeks after a single dose. Response rates exceeded those typically seen with conventional antidepressants in TRD populations.
Regulatory Path
COMP360 has FDA Breakthrough Therapy Designation, which provides expedited review. Compass is expected to file its New Drug Application (NDA) in late 2026, with potential approval in early 2027. If approved, it would become the first psilocybin-based treatment authorized by the FDA.
Industry Implications
Approval of COMP360 would validate the entire psychedelic medicine sector and open the door for other compounds in development. The $350M capital raise demonstrates that institutional investors are now treating psychedelic medicine as a legitimate pharmaceutical category rather than a speculative bet.
